General Information of Drug (ID: DM3FPAQ)

Drug Name
Anifrolumab
Indication
Disease Entry ICD 11 Status REF
Systemic lupus erythematosus 4A40.0 Approved [1]
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 907 mgday/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 82.4 mg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.72 h [2]
Clearance
The sytemic clearance of drug is 0.193 L/day [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.84 days (for a 0.1 mg/kg single dose) [4]
Metabolism
The drug is metabolized via the catabolized to smaller oligopeptides and individual amino acids [5]
Vd
The volume of distribution (Vd) of drug is 6.23 L [3]
Cross-matching ID
DrugBank ID
DB11976
TTD ID
D0FU8R

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon alpha/beta receptor 2 (IFNAR2) TTMQB37 INAR2_HUMAN Antagonist [6]
Interferon gamma receptor (IFNGR2) TT13TL0 INGR2_HUMAN Antagonist [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761123.
2 Tummala R, Rouse T, Berglind A, Santiago L: Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med. 2018 Mar 23;5(1):e000252. doi: 10.1136/lupus-2017-000252. eCollection 2018.
3 FDA Approved Drug Products: Saphnelo (Anifrolumab-fnia) Intravenous Injection
4 Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014 Feb 24;16(1):R57. doi: 10.1186/ar4492.
5 Veve MP, Wagner JL: Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)